Board summary
Key figures
39,636
Registered population
55.7% aged 18–64
24.4%
Aged 65+
ICB 19.9% · England 17.9%
8.3%
Ethnic minority (non-White)
3.6% Asian · England 9.6%
4.6%
In IMD quintile 1
ICB 17.1% · England 21.0%
~1,718
Core20 residents (est.)
Resident basis; registered basis ~1,926 · see page 3
7,618
Hypertension register
+3.97% in 3 yrs · England +5.60%
238
SMI register
8.4% of Medway (LAD)'s
690
COPD register
Reviews -14.97% in 3 yrs
Forecast to 2030
8,536
Hypertension patients, 2030
+918 on today
75.0%
QRISK ≥20% on statins, 2030
+4.88pp over 3 yrs
5.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual review coverage fell over three years.
Asthma reviews fell 21.7% (England +4.4%) to 60.7% (England 65.7%), a scale of about 920 unreviewed patients, which may reflect unverified recall lags.
Core20 deprivation is concentrated in two practices.
Practice Core20 shares span 46.9 pp, reaching 46.9% at Waltham Road Medical Centre (620 estimated patients) and 22.9% at Eastcourt Lane Surgery (534).
Older-adult blood pressure control exceeds national benchmarks.
Blood pressure control in patients aged 80+ is 86.4% (England 81.2%; Medway (LAD) 79.4%), rising +6.3% over three years against England's +2.2%.
Population, age and ethnicity
Older adults aged 65+ make up 24.4% of patients, exceeding England's 17.9%
Medway Rainham PCN serves 39,636 registered patients across eight practices. The population is older than benchmarks: 24.4% (9,685 patients) are aged 65+, above Medway (LAD) (17.9%), NHS Kent and Medway ICB (19.9%), and England (17.9%). Working-age adults represent 55.7% (22,068 patients) and children 19.9% (7,883 patients). Projected list growth to 2030 is +2.5% (Medway (LAD) +7.0%, ICB +6.0%, England +2.3%; unverified methodology). Census resident data, not registered ethnicity, records 91.7% White (Medway (LAD) 84.3%, ICB 88.6%, England 81.1%) and 3.6% Asian / Asian British (Medway (LAD) 5.9%, ICB 4.7%, England 9.6%).
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Medway (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Medway LA) | 1,507 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.7% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.4% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Medway LA) | 740 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Medway LA) | 19.5 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Overall Core20 deprivation is 4.6% but practice shares span 46.9 percentage points
Medway Rainham PCN's Core20 share is 4.6%, below Medway (LAD) at 23.1%, NHS Kent and Medway ICB at 17.1%, and England at 21.0% (average IMD decile 6.9). Practice shares span 46.9 pp, concentrated at Waltham Road Medical Centre (46.9%, 620 estimated patients) and Eastcourt Lane Surgery (22.9%, 534 patients). Registered practice estimates total 1,926 patients, differing from the 1,718 resident estimate. Targeted outreach and proactive reviews should prioritise these two concentrated practices rather than diluting resources across the PCN.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
238
SMI register
0.60% recorded prevalence
183
Learning disability register
0.46% recorded prevalence
13
Care homes, 358 beds
In the PCN catchment
8.9%
Provide unpaid care
Medway (LAD), Census 2021
The PCN records 238 patients on the severe mental illness register (0.6%) and 183 on the learning disability register (0.5%), both trailing Medway (LAD) (0.9%, 0.7%), NHS Kent and Medway ICB (0.9%, 0.6%), and England (1.0%, 0.6%). Catchment services include 13 care homes (358 beds). Separately, Medway (LAD) reports an 8.9% unpaid care rate and 11 rough sleepers in 2025.
Severe mental illness: physical health checks
SMI prevalence is 0.6% (England 1.0%). Annual BP checks reach 84.6% (England 83.4%) and BMI checks reach 83.4% (England 82.1%), but alcohol recording fell 1.3 pp over three years (England +5.4 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,618
Hypertension register
+3.97%
Register growth, 3 yrs
Medway (LAD) +3.74% · England +5.60%
+0.18pp
BP control, under 80
≤140/90 · +5.10pp aged 80+
+918
More patients by 2030
Forecast 8,536 (20.80%)
Hypertension case-finding and control
Hypertension prevalence is 19.2% (7,618 patients), above Medway (LAD) (15.4%), NHS Kent and Medway ICB (16.2%) and England (15.2%), though crude prevalence is not age-adjusted. Blood pressure control in patients aged 80+ is 86.4% (England 81.2%), rising +6.3% over three years (England +2.2%). Conversely, recent blood pressure recording stands at 87.9% (England 90.0%) after slower three-year growth of +1.9% (England +3.6%). Furthermore, three-year control progress for under-80s (+0.3%) trails England (+3.2%), despite current control reaching 71.5% (England 67.8%). Slower three-year control progress for under-80s compared with England suggests reviewing working-age recall and titration processes.
Lipids and statins
Lipid-lowering therapy reaches 64.0% of patients with QRISK ≥ 20%, in line with Medway (LAD) (64.0%) and above England (63.6%). Statin treatment is 74.8% in chronic kidney disease (England 70.3%) and 74.7% for primary prevention in diabetes (England 73.2%). Treatment coverage exceeds England across high-risk groups, so the priority is sustaining proactive recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 75,462 | £2.40 | £1.90 | £1.86 | £181,109 |
| Cardiovascular (all), 2025 | 84,445 | £3.44 | £3.57 | £3.33 | £290,491 |
In 2026, lipid-modifying prescribing cost £2.40 per item, above Medway (LAD) (£1.87), NHS Kent and Medway ICB (£1.90) and England (£1.86). Across 75,462 items, spend is £40,749 more than at England's unit cost. Prescribing unit costs exceed benchmarks, indicating an opportunity for clinical pharmacists to review lipid-modifying formulary choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−21.69%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.52%
Asthma prevalence, PCN 3-yr % change
Asthma annual review coverage fell 21.7% over three years to 60.7% (England +4.4% to 65.7%; Medway (LAD) 62.6%), leaving an unadjusted scale of about 920 of 2,339 registered asthma patients without a recorded review. COPD reviews similarly dropped 15.0% to 70.6% across 690 patients (England +2.8% to 76.4%; Medway (LAD) 74.3%). Conversely, youth asthma second-hand smoking status recording reached 89.1% (England 78.8%). Falling adult reviews across both pathways may indicate recall capacity pressures or coding delays, unverified locally.
Cancer register and children's immunisation
Recorded cancer prevalence is 4.7% (1,871 patients; England 3.8%). In childhood immunisations, 24-month completion exceeds the 95.0% target (6-in-1 at 97.5%, MMR dose 1 at 96.2%). However, 12-month 6-in-1 coverage is 89.3% (below target by 5.7 pp; England 91.0%), and age-5 MMR dose 2 is 90.9% (below target by 4.1 pp), with a 20 pp dose difference at Eastcourt Lane Surgery. Catch-up call-and-recall should focus on pre-school boosters and infant immunisation timeliness.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
Cancer stage at diagnosis is not published at PCN level. In NHS Kent and Medway ICB, 55.6% of cancers were diagnosed at stage 1 or 2 in 2022 (4,661 of 8,384 with known stage; England 55.3%; distance to National ambition by 2028: -19.4 pp). Staging was known for 63.6% of ICB cancers (8,384 of 13,189; England 67.0%), an illustrative gap of about 1,630 early-stage cases. At PCN level, cervical screening coverage (ages 25-49) is 75.5% (England 66.8%), with a 3-year change of -2.7% (England -1.0%, Medway (LAD) +2.6%), falling to 67.9% at Long Catlis Road Surgery and 74.5% at Eastcourt Lane Surgery.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
Cancer waits describe provider performance rather than PCN referrals. Medway NHS Foundation Trust exceeded the 75.0% 28-day faster diagnosis standard by 2.8 pp and the 96.0% 31-day combined treatment standard by 3.6 pp. However, the trust fell below the 85.0% 62-day referral to treatment standard by 3.4 pp. Across NHS Kent and Medway Integrated Care Board, 62-day performance was 9.1 pp below the 85.0% standard, while 28-day faster diagnosis was 1.8 pp above the 75.0% standard.
| Pathways within standard (%) | Medway | Maidstone and Tunbridge Wells | Mid and South Essex | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.77 | 81.78 | 67.45 | 76.78 | 79.32 |
| 31-day treatment (96%) | 99.62 | 98.35 | 81.88 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 81.64 | 87.43 | 50.25 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Medway | Maidstone and Tunbridge Wells | Mid and South Essex | England |
|---|---|---|---|---|
| MRI | 0.68 | 0.92 | 23.35 | 21.40 |
| CT | 0.00 | 0.51 | 6.07 | 9.92 |
| Echocardiography | 36.62 | 2.57 | 65.05 | 28.48 |
| Colonoscopy | 1.88 | 19.80 | 64.09 | 30.83 |
| Gastroscopy | 3.32 | 24.03 | 59.76 | 29.02 |
| All 15 DM01 tests | 14.20 | 6.42 | 41.54 | 23.14 |
| Community services activity | Medway residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 43,510 | 254,055 |
| Referrals | 8,580 | 68,085 |
| Patients with a contact | 11,540 | 72,060 |
Community services (residents of Medway), Jun 2026 (provisional). In Medway, community health service activity recorded 43,510 contacts with local authority residents in Jun 2026 (provisional), of which 26,985 involved adults aged 65 and over, a 62% share. While these borough figures show substantial older-adult contact volume across community services, they represent resident activity rather than PCN-specific delivery.
Practice variation and patient experience
Phone access spans 49.1 pp and vaccination achievement spans 61.6 pp across practices
In 2025/26, QOF vaccination and immunisation achievement spanned 61.6 pp across practices, from 38.4% at Orchard Family Practice to 100.0% at Waltham Road Medical Centre. Overall QOF achievement was 65.3% at Long Catlis Road Surgery and 100.0% at Waltham Road Medical Centre. Clinical domain achievement was 63.4% at Long Catlis Road Surgery and 100.0% at Waltham Road Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Maidstone Rd | 114 | 0.0 | 93.1% | 75.7% | 94.8% |
| Thames Ave Surgery | 116 | 2.4 | 84.9% | 68.9% | 93.8% |
| Orchard | 106 | 6.6 | 68.2% | 63.4% | 92.8% |
| Waltham Road | 110 | 46.9 | 84.8% | 46.6% | 91.2% |
| Eastcourt Lane | 103 | 22.9 | 86.6% | 58.2% | 84.4% |
| Parkwood | 128 | 0.0 | 55.4% | 55.8% | 77.7% |
| Wigmore | 102 | 0.0 | 61.4% | 68.4% | 71.7% |
| Long Catlis Road | 110 | 2.4 | 44.0% | 57.1% | 71.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 three-year measures trail England, despite strong older-adult cardiovascular progress
Fourteen of 25 compared measures trail England's three-year trajectory. Annual asthma reviews fell 21.7% over three years to 60.7% (England +4.4%), COPD reviews fell 15.0% to 70.6% (England +2.8%), and psychosis alcohol recording fell 1.3 pp (England +5.4 pp). Learning disability prevalence also fell 1.9% to 0.5% (England +5.4%). Conversely, chronic care delivery improved in heart failure reviews (+14.6% vs England +8.7%), older-adult blood pressure control (+6.3% vs England +2.2%), and non-frail diabetes HbA1c control (+8.0% vs England +4.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
COPD reviews
Learning disability register
Alcohol record (psychosis)
BP control, under 80
Heart failure reviews
BP control, 80+
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Medway (LAD) | Asset | PCN | Medway (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (358 beds) | n/a | Schools (catchment) | 54 | n/a |
| Children's centres | 4 | 19 | Places of worship | 29 | 110 |
| Libraries | 2 | 9 | Food banks (VCS) | n/a | 6 |
| Homelessness support (VCS) | n/a | 9 | Day centres (VCS) | 6 | 29 |
| Children and young people (VCS) | 12 | 65 | Carers support groups (VCS) | 1 | 22 |
| Primary schools (LA maintained) | 8 | 17 | Primary academies | 12 | 56 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Respiratory annual review recall redesign
Asthma reviews fell 21.7% over 3 years to 60.7% (England +4.4% to 65.7%), an unadjusted scale of about 920 of 2,339 patients unreviewed; COPD fell 15.0% to 70.6% (690 patients). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Learning disability register validation audit
Learning disability prevalence is 0.5% (183 of 39,636 registered patients) after a 1.9% 3-year fall (England 0.6%, +5.4%; Medway (LAD) 0.7%, +4.3%), a modelled gap of +50 to +90 patients. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 3
Under-eighty hypertension and lipid review
Hypertension BP recording is 87.9% (England 90.0%) and under-80s control rose +0.3% over 3 years (England +3.2%); lipid-modifying drugs cost £2.40 per item, £40,749 more than England's £1.86 across 75,462 items. For discussion: clinical pharmacists could combine under-80s blood pressure recall and titration with a formulary review of lipid-modifying prescribing. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted deprivation review clinics (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness check review (p4) | Patients with psychosis who have a current record of alcohol consumption | MHIS · From Harm to Hope | PCN |
| Under-eighty blood pressure recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Respiratory annual review recall redesign (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · Learning disability register validation audit (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 3 · Under-eighty hypertension and lipid review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
